Form 4: Xencor Director Barbara Klencke Receives Significant Equity Awards

Xencor Inc. Director Barbara Klencke was granted 13,686 restricted stock units and 27,372 stock options on June 12, 2025, as part of her compensation.

Summary

• Xencor Inc. Director Barbara Klencke received equity awards on June 12, 2025.
• The awards include 13,686 shares of common stock in the form of restricted stock units (RSUs).
• These RSUs were granted at a price of $0 and are set to fully vest on the first anniversary of the grant date.
• Additionally, Ms. Klencke was granted 27,372 stock options with an exercise price of $9.43.
• The stock options have an expiration date of June 11, 2035, and will vest in equal monthly installments over one year, beginning one month after the grant date, fully vesting by June 12, 2026.
• Following these transactions, Ms. Klencke beneficially owns 19,672 shares of common stock and 27,372 stock options.
• The Form 4 filing was signed by Celia E. Eckert as Attorney-in-Fact for Barbara Klencke, under a Power of Attorney executed on February 19, 2025.

Sentiment

Score: 7

Explanation: The grant of equity awards to a director is a positive sign of continued alignment of interests between the board and shareholders, and is a standard component of executive compensation, indicating stability and ongoing commitment.

Positives

• The grant of equity awards to a director aligns her interests with those of the shareholders, incentivizing long-term performance.
• The awards represent a standard form of compensation for board members, indicating continued commitment to the company.

Future Outlook

The vesting schedules for the restricted stock units and stock options indicate future increases in the director's vested equity holdings in the company, with full vesting of RSUs by June 12, 2026, and stock options by June 12, 2026.

Industry Context

The grant of equity awards to a director is a standard practice in publicly traded companies, particularly in the biotechnology sector like Xencor, serving as a key component of executive and board compensation to align interests with long-term shareholder value.

Comparison to Industry Standards

• This equity grant is consistent with typical compensation structures for non-employee directors in the biotechnology industry, which often include a mix of cash and equity awards to incentivize performance and retention.
• Specific comparable companies or projects are not detailed in the filing to allow for a direct quantitative comparison of the award size.

Corporate Governance

Related Party Transactions

• The grant of 13,686 restricted stock units and 27,372 stock options to Director Barbara Klencke constitutes a related party transaction, as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The equity awards align the director's financial interests with long-term shareholder value, potentially leading to more shareholder-centric decision-making.
• Employees: No direct impact on general employees is mentioned in this filing.

Next Steps

• Vesting of 13,686 restricted stock units on the first anniversary of the grant date (June 12, 2025).
• Continued monthly vesting of 27,372 stock options over one year, fully vesting by June 12, 2026.

Key Dates

Recommendation

Keywords

Xencor, XNCR, SEC Form 4, insider transaction, equity award, restricted stock units, stock options, director compensation, beneficial ownership